BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andrade AF, Borges KS, Suazo VK, Geron L, Corrêa CA, Castro-Gamero AM, de Vasconcelos EJ, de Oliveira RS, Neder L, Yunes JA, Dos Santos Aguiar S, Scrideli CA, Tone LG. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. Invest New Drugs 2017;35:26-36. [PMID: 27785591 DOI: 10.1007/s10637-016-0401-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Srivastava R, Lodhi N. DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1. Biomolecules 2022;12:417. [DOI: 10.3390/biom12030417] [Reference Citation Analysis]
2 Priyadarshini M, Maji S, Samal SK, Rath R, Li J, Das SK, Emdad L, Kundu CN, Fisher PB, Dash R. SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress. Life Sci 2021;287:120141. [PMID: 34774620 DOI: 10.1016/j.lfs.2021.120141] [Reference Citation Analysis]
3 Abballe L, Miele E. Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. World J Stem Cells 2021; 13(7): 670-684 [PMID: 34367473 DOI: 10.4252/wjsc.v13.i7.670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Strejczek A, Woszczyk D, Urbaniak H, Różańska M, Robak M, Matuszewska Z, Barciszewska AM. Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery. Int J Mol Sci 2021;22:4925. [PMID: 34066495 DOI: 10.3390/ijms22094925] [Reference Citation Analysis]
5 Zhang X, Liu Y, Dai L, Shi G, Deng J, Luo Q, Xie Q, Cheng L, Li C, Lin Y, Wang Q, Fan P, Zhang H, Su X, Zhang S, Yang Y, Hu X, Gong Q, Yu D, Zheng L, Deng H. BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. Oncogene 2021;40:1516-30. [PMID: 33452462 DOI: 10.1038/s41388-020-01627-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Wang Q, Dai L, Wang Y, Deng J, Lin Y, Wang Q, Fang C, Ma Z, Wang H, Shi G, Cheng L, Liu Y, Chen S, Li J, Dong Z, Su X, Yang L, Zhang S, Jiang M, Huang M, Yang Y, Yu D, Zhou Z, Wei Y, Deng H. Targeted demethylation of the SARI promotor impairs colon tumour growth. Cancer Letters 2019;448:132-43. [DOI: 10.1016/j.canlet.2019.01.040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
7 Huang D, Cui L, Ahmed S, Zainab F, Wu Q, Wang X, Yuan Z. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs. Food and Chemical Toxicology 2019;123:574-94. [DOI: 10.1016/j.fct.2018.10.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
8 Zwergel C, Romanelli A, Stazi G, Besharat ZM, Catanzaro G, Tafani M, Valente S, Mai A. Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. Front Pediatr 2018;6:370. [PMID: 30560106 DOI: 10.3389/fped.2018.00370] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Geron L, Salomão KB, Borges KS, Andrade AF, Corrêa CAP, Scrideli CA, Tone LG. Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines. Cytotechnology 2018;70:1713-22. [PMID: 30374857 DOI: 10.1007/s10616-018-0260-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Yang Q, Ali M, El Andaloussi A, Al-Hendy A. The emerging spectrum of early life exposure-related inflammation and epigenetic therapy. Cancer Stud Mol Med 2018;4:13-23. [PMID: 30474062 DOI: 10.17140/CSMMOJ-4-125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Agrawal K, Das V, Vyas P, Hajdúch M. Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic. Pharmacology & Therapeutics 2018;188:45-79. [DOI: 10.1016/j.pharmthera.2018.02.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
12 Takemura Y, Satoh M, Hatanaka K, Kubota S. Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells. Biosci Biotechnol Biochem 2018;82:1159-64. [PMID: 29685095 DOI: 10.1080/09168451.2018.1459466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Yi J, Wu J. Epigenetic regulation in medulloblastoma. Mol Cell Neurosci 2018;87:65-76. [PMID: 29269116 DOI: 10.1016/j.mcn.2017.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kanemaru H, Yamane F, Fukushima K, Matsuki T, Kawasaki T, Ebina I, Kuniyoshi K, Tanaka H, Maruyama K, Maeda K, Satoh T, Akira S. Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages. Proc Natl Acad Sci U S A 2017;114:E7331-40. [PMID: 28808017 DOI: 10.1073/pnas.1708598114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]